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Abstract HIV-Associated Neurocognitive Disorders
(HAND) is a common manifestation of HIV infection that
afflicts about 50 % of HIV-positive individuals. As people
with access to antiretroviral treatments live longer, HAND can
be found in increasing segments of populations at risk for
other chronic, neurodegenerative conditions such as
Alzheimer’s disease (AD) and Multiple Sclerosis (MS). If
brain diseases of diverse etiologies utilize similar biological
pathways in the brain, they may coexist in a patient and
possibly exacerbate neuropathogenesis and morbidity. To test
this proposition, we conducted comparative meta-analysis of
selected publicly available microarray datasets from brain
tissues of patients with HAND, AD, and MS. In pair-wise
and three-way analyses, we found a large number of dysregu-
lated genes and biological processes common to either HAND
and AD or HAND and MS, or to all three diseases. The
common characteristic of all three diseases was up-regulation
of broadly ranging immune responses in the brain. In addition,
HAND andAD share down-modulation of processes involved,
among others, in synaptic transmission and cell-cell signaling
while HAND and MS share defective processes of
neurogenesis and calcium/calmodulin-dependent protein ki-
nase activity. Our approach could provide insight into the
identification of common disease mechanisms and better inter-
vention strategies for complex neurocognitive disorders.
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Introduction
HIV infection can cause a wide spectrum of central nervous
system (CNS) complications ranging frommild neurocognitive
impairments to incapacitating dementias that have been recent-
ly grouped under the term HIV-associated neurocognitive dis-
orders or HAND (Antinori et al. 2007). Historically, HIV-
associated dementia (HIV-D or HAD) was the most prominent
manifestation of HIV-mediated brain disease (Epstein et al.
1986; Navia and Price 1987). The introduction of highly effi-
cacious antiretroviral therapies (ART) has markedly reduced
the prevalence of HAD but it has had a limited effect on the two
other major manifestations of HAND, the HIV-associated
asymptomatic neurocognitive impairment (ANI) and the HIV-
associated mild neurocognitive disorder (MND) (Sacktor et al.
2002; Ellis et al. 2007; Robertson et al. 2007). By some
accounts, up to 50 % of HIV-infected individuals will develop
some form of neurocognitive impairment despite access to
ART (Ellis et al. 2007; Heaton et al. 2010; Simioni et al.
2010; Harezlak et al. 2011). As HIV infection has become a
chronic and manageable condition under ART (Richman
2001), the populations at risk of HANDmay begin overlapping
with populations prone to other chronic diseases of the central
nervous system such as AD (Alisky 2007; Pulliam 2009) and
MS (Berger et al. 1992; Lackner et al. 2010). If brain diseases
of diverse etiologies utilize common biological pathways in the
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nervous system, coexistence of such pathologies in a patient
may lead to increased morbidity. On the other hand, identifica-
tion of such common pathogenic pathways may suggest com-
mon therapeutic approaches to diverse diseases.
A number of commonalities between HAND and other
neurodegenerative diseases were revealed by studies of in-
dividual disease determinants. For example, in some
patients HIV infection was shown to correlate with the
presence of leukoencephalomyelopathy and MS-like illness
(Berger et al. 1992; Corral et al. 2004). In a recent cross-
sectional cohort study, HAND was shown to correlate with
presence of auto-antibodies to myelin oligodendrocyte gly-
coprotein, including in patients on ART with suppressed
plasma HIV (Lackner et al. 2010), suggesting that HAND
and MS neuropathogenesis may overlap in the pathway of
aberrant myelin breakdown. Consistent with this finding,
our recent microarray analysis of brain tissues from
HAND patients on ART revealed significant down-
modulation of several myelin metabolism-related genes in-
cluding myelin-associated oligodendrocyte basic protein
(MOBP), myelin transcription factor 1 (MYT1) and myelin
basic protein (MBP) (Borjabad et al. 2011). On the other
hand, HIV Tat was shown to inhibit neprilysin and elevate
amyloid-beta in fetal human brain spheres in culture and
amyloid-beta was elevated in postmortem brain tissues of
patients with HAND (Rempel and Pulliam 2005), suggest-
ing one common pathway in HAND and AD pathogenesis
in older individuals. This notion is supported by recent
proteomic analysis of postmortem frontal cortex tissues
from HIV positive patients with or without HAD, which
revealed aberrant expression of proteins involved in glycol-
ysis and oxidative phosphorylation specifically in HAD
tissues and noted similar pathway changes in other dementia
conditions including Alzheimer’s and Parkinson’s diseases
(Zhou et al. 2010). Broader patterns of similarity between
HAND and diseases such as AD and MS were suggested
based on review of macrophage/microglia and astrocyte
functions in neuropathogenesis (Minagar et al. 2002), re-
view of dysregulation of specific genes in these pathologies
(Minagar et al. 2004), and bioinformatics-aided analysis of
potential parallels in chromosomal localization, expression
and function of dementia-associated genes between HAND
and AD (Shapshak et al. 2008). Indeed, a recent review by
Noorbakhsh et al. presented a convincing case for the power
of integrative analysis of data-rich studies involving func-
tional genomics, proteomics, and other systems biology
approaches in discerning convergent pathways of human
neuropathogenesis (Noorbakhsh et al. 2009).
In the present study we used publicly available functional
genomic data and bioinformatics tools to conduct for the
first time a comparative analysis of gene expression profiles
of brain tissues of HAND, AD, and MS. Genome-wide
microarray analysis of coordinated changes in gene
expression is one of the most established platforms for
integrated understanding of global phenotypic changes
occurring during transition from normal to pathological
states, including in the central nervous system (D’Agata
and Cavallaro 2004; Grunblatt 2004; Blalock et al. 2005;
Noorbakhsh et al. 2009; Bossers et al. 2010; Cooper-Knock
et al. 2012). Our objective was to identify altered gene
expression motifs in brain tissues that may indicate conver-
gence of pathogenic mechanisms driving development of
HAND and one or both of the other two neurodegenerative
conditions in this study. A rich microarray database from
multiple studies exists for AD and MS (for reviews, see
(Katsel et al. 2005; Lindberg and Kappos 2006; Tajouri et
al. 2007; Kinter et al. 2008)). The respective database from
HAND brain tissues is less extensive but it nevertheless
encompasses analyses of over 60 HAND patients and con-
trols in five studies (Gelman et al. 2004; Masliah et al. 2004;
Shapshak et al. 2004; Everall et al. 2005; Borjabad et al.
2011). The meta-analysis of these datasets revealed numer-
ous aberrant gene expression changes and alterations in
biological pathways that were common to HAND and AD
and HAND and MS in two-way analyses, and that were
overlapping for all three diseases in a three-way comparison.
Materials and methods
Selection of gene expression datasets from brain tissues
of individuals with HAND, AD, and MS for comparative
analysis
The microarray studies of the three neurodegenerative dis-
eases of interest were identified through search of publicly
available gene expression databases, primarily PubMed and
Gene Expression Omnibus (GEO) at the National Center for
Biotechnology Information (NCBI) (http://www.ncbi.nlm.
nih.gov/). The studies selected for this work are listed in
Tables 1 and 2. We considered only microarray studies
conducted with human post-mortem brain tissue, excluding
animal and tissue culture models of these diseases. The
choice of brain anatomical regions included in our analyses
is explained in Results. To facilitate comparison among
diverse microarray datasets only studies that used control
groups and expressed results as differential gene expression
(fold change) between tested biological state and control
were selected. Finally, we excluded studies that provided
insufficient information about microarray analysis.
Meta-analysis of gene expression profiles
The microarray datasets selected for the current analysis
were obtained on various microarray platforms that used
different experimental protocols and analytical methods
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(for example, (Masliah et al. 2004; Stephens et al. 2006;
Bossers et al. 2010)); the microarray platforms are listed in
Tables 1 and 2. To overcome the difficulty inherent in
comparing raw microarray datasets from a variety of sources
(Tan et al. 2003; Parmigiani et al. 2004; Borjabad et al.
2010), we elected to use second-level derivative datasets
representing statistically significant changes in gene expres-
sion for each disease under study. Such changes are calcu-
lated according to widely acceptable standards for defining
statistical significance of differential gene expression
(Blalock et al. 2005; Hoheisel 2006) and thus this approach
allowed us to compare various datasets independently of
microarray platform or statistical approach used. To further
facilitate comparison of genes listed by various sources, we
standardized gene nomenclature in the present work to
GenBank gene symbol identifiers (http://www.ncbi.nlm.
nih.gov/genbank/). This permitted us to overcome the
inconsistencies of gene nomenclature and to normalize gene
identity across the datasets. It should be noted that some of
the genes listed in the present analysis have a different gene
ID than in the original report as a result of public database
updates. Following these preparatory analyses, we pooled
the sets of differentially expressed genes listed in each
publication within each brain disease group (HAND, treated
HAND, AD, and MS). Because our purpose was to generate
a comprehensive, brain disease-specific transcriptome incor-
porating multiple independent studies, we listed each sig-
nificantly aberrant gene in a given disease group only once
and did not assign to genes any additional value besides
direction of dysregulation, regardless of whether they were
listed in one or multiple publications. The HAND, AD, and
MS profiles were then compared in two-way and three-way
analyses using the Microsoft database management system
Access software to identify common (overlapping) genes.
The final common gene datasets were then analyzed by func-
tional categorization of gene families using gene ontology
program Expression Analysis Significance Explorer (EASE)
(Hosack et al. 2003) (http://david.abcc.ncifcrf.gov/) and the
Affymetrix NetAffx™ Analysis Center (http://www.
affymetrix.com/analysis/index.affx).
Results
Brain transcriptome profiles in HAND and ART-HAND
As of this writing, five published reports employed func-
tional genomics to examine gene expression profiles in
brain tissues from patients who died with HAND (Gelman
et al. 2004; Masliah et al. 2004; Shapshak et al. 2004;
Everall et al. 2005; Borjabad et al. 2011); these reports are
listed in Table 1. The Table also provides information on the
anatomical brain region and microarray platforms used, and
the biological states compared in each study. Three studies
examined gene expression patterns in the frontal cortex; one
study tested both cortex and subcortical white matter, and
one study focused on deep white matter from the frontal
lobe region. Three studies used the Affymetrix U95Av2
microarray platform and two were conducted with the
new-generation Affymetrix HG-U133 platform. Two
HAND array studies used in our analysis show relatively
limited sets of gene expression data focusing on the specific
HAND disease pathology of HIV-associated encephalitis,
HIVE (Masliah et al. 2004; Everall et al. 2005). The initial
HIVE analysis employed datasets from HAD patients with-
out HIVE as controls (no HIV negative controls were used),
and it identified a total of 133 differentially expressed genes
specific to HIVE (Masliah et al. 2004). A follow-up study in
the same patient cohort stratified microarray datasets by
patient methamphetamine addiction, demonstrating a strong
correlation between drug use and induction of interferon-
related genes (Everall et al. 2005). Additional studies based
on HIVE-specific datasets were not included because they
focus on individual genes already represented in these arrays
rather than new array analyses (Everall et al. 2006; Salaria et
al. 2007). Two other studies listed in Table 1 (Gelman et al.
2004; Shapshak et al. 2004) examined HIV-infected versus
uninfected brain tissues; although these works show only
partial datasets or derivative analyses they were included to
increase the power of our analysis. The most recent study
listed in Table 1 (Borjabad et al. 2011) analyzed postmortem
HAND brain tissue versus HIV negative controls; patient
Table 1 Published gene expression profiles from HAND brain tissues used in the present analysis
Author Year Brain area tested Microarray platform Biological states compared
Masliah 2004 Frontal cortex Affymetrix U95Av2 HIVE vs non HIVE
Gelman 2004 Frontal cortex and white matter Affymetrix HG-U133 HAND-MCMD-NPI-O vs HIV neg
Shapshak 2004 Frontal cortex Affymetrix U95Av2 HIV vs HIV neg
Everall 2005 Frontal cortex Affymetrix U95Av2 HIVE vs non HIVE
Borjabad 2011 Frontal lobe white matter Affymetrix HG-U133 untreated HAND vs HIV neg
Borjabad 2011 Frontal lobe white matter Affymetrix HG-U133 treated HAND vs HIV neg
5 papers: 1132 up-regulated and 779 down-regulated genes
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datasets were stratified by the antiretroviral treatment (ART)
status of subjects at the time of death. This approach yielded
two distinct HAND brain microarray profiles, one represent-
ing untreated patients and consisting of 1,470 dysregulated
Table 2 Published gene expression profiles from AD and MS brain tissues used in the present analysis
Author Year Brain area tested Microarray platform Biological states compared
Alzheimer’s disease
Hata 2001 Hippocampus Incyte Pharmaceuticals,
UniGem V microarray
AD vs non AD
Loring 2001 Amygdala/cingulate cortex Incyte Genomics, Unigene Lifearray AD vs non AD
Ho/Pasinetti 2001 Cortex Incyte Pharmaceuticals,
UniGem V microarray
early/moderate AD vs non AD
Colangelo 2002 Hippocampus CA1 Affymetrix U95A AD vs non AD
Walker 2004 Frontal Cortex The Microarray Center, University
Health Network, Toronto
AD vs non AD
Ricciarelli 2004 Frontal Cortex Clontech, Atlas Human 12K
Microarray
AD vs non AD with amyloid
plaques
Lukiw 2004 Hippocampus Affymetrix U95A fetal - adult - AD
Small 2005 Entorhinal cortex/dentate gyrus Affymetrix HG-U133 AD vs non AD
Emilsson 2006 Frontal Cortex Uppsala University and Royal
Institute of Technology
AD vs non AD
Parachikova 2007 Frontal Cortex/Hippocampus Affymetrix U95A mild-moderate AD vs non AD
high pathology
Katsel 2007 17 regions Affymetrix HG-U133 different stages AD vs non AD
Brooks 2007 Hippocampus Affymetrix HG-U133 metabolic genes
Weeraratna 2007 Parietal lobes Agilent Human
44K microarray





Affymetrix HG-U133 AD and PD vs non AD non PD
Katsel 2009 15 regions Affymetrix HG-U133 youngest-old/oldest-old AD
and non AD
Williams 2009 Synaptoneurosomes from
Prefrontal Cortex
Affymetrix HG-U133 incipient AD vs non AD
Tan 2010 Neocortex (temporal cortex) Affymetrix GeneChip Human
Exon 1.0 ST Arrays
AD vs non AD
Bossers 2010 Prefrontal Cortex Agilent Human 44K microarray comparison different AD stages
18 papers: 5185 up-regulated and 3684 down-regulated genes
Multiple sclerosis
Whitney 1999 White matter Custom-made cDNA microarrays acute lesions vs normal white
matter
Lock 2002 White matter Affymetrix HuGeneFL7026
microarrays
MS active or silent lesions
vs control
Tajouri 2003 White matter Custom-made fluorescent cDNA
microarrays
MS chronic or acute lesions
vs control
Mycko 2003 White matter Clontech Atlas Glass Human 1.0 Margin/centre - active/silent lesions
Graumann 2003 White matter Clontech Atlas cDNA Expression Array normal-appearing vs control
Lindberg 2004 White matter Affymetrix U95A normal-appearing and active
lesions vs control
Dutta 2006/2007 Cortex Affymetrix HG-U133 MS vs control
Zeis 2008 White matter Clontech Atlas cDNA Expression Array normal-appearing vs control
Torkildsen 2010 Cortex Applied Biosystems normal-appearing and lesions
vs controlHuman Genome Survey Microarray v1.0
9 papers: 3922 up-regulated and 4171 down-regulated genes
J Neuroimmune Pharmacol (2012) 7:914–926 917
genes and the second representing treated patients and con-
sisting of 253 dysregulated genes, the majority of which
were also dysregulated in untreated subjects (Borjabad et al.
2011). To construct the representative HAND brain profile
for comparison with AD and MS profiles, we pooled all
datasets listed in Table 1 including transcriptomes from both
treated and untreated patients described in Borjabad et al.
(Borjabad et al. 2011). This approach was taken because the
other HAND studies listed in Table 1 did not provide infor-
mation on ART status of their patient cohorts and thus they
could include either treated, untreated, or both categories of
patients. This profile was termed HAND and it was found to
consist of (excluding multiply listed genes, see Methods)
1,132 up-regulated and 779 down-regulated HAND-
associated genes (Table 1).
Because ART clearly mitigated cellular gene expression
in the brain of patients with HAND compared to that in
untreated patients (Borjabad et al. 2011), we designated a
second category of HAND transcriptomes called ART-
HAND which contained only datasets of HAND patients
known to be on treatment prior to death. Patients in this
category, in a single study published so far, continued to
manifest cognitive disease in the last evaluation prior to
death (Borjabad et al. 2011). These results were interpreted
as being indicative of fundamental gene expression changes
in the brain leading to HAND (Borjabad et al. 2011) and
they could possibly be involved in AD and MS as well. The
ART-HAND dataset contains 128 significantly up-regulated
and 125 down-regulated genes (Borjabad et al. 2011).
Transcriptome profiles in AD and MS
Table 2 lists microarray studies in AD and MS brain tissues
selected for comparison with HAND transcriptomes. The
criteria for study selection are described in Methods and
below. The Table also provides information on the anatomical
brain region and microarray platform used, and the biological
states compared in each study. AD is at present the most
common form of dementia including progressive memory
loss, decline in cognitive functions, and other behavioral
symptoms. Gene and protein changes in AD have been ex-
tensively studied and numerous functional genomics analyses
have also been reported including studies in animal models of
AD (Jee et al. 2007; Prinzen et al. 2009; Tseveleki et al. 2010),
isolated brain cells (Counts et al. 2007; Ginsberg et al. 2010),
and post-mortem human brain tissue. In human AD brain, the
main areas of analysis are the cortex (Pasinetti 2001;Walker et
al. 2004; Emilsson et al. 2006) and hippocampus (Colangelo
et al. 2002; Blalock et al. 2004; Brooks et al. 2007), two areas
implicated in the pathobiology of AD. Other studies analyzed
and compared different areas of the brain (Grunblatt et al.
2007; Katsel et al. 2007; Parachikova et al. 2007), or focused
on specific molecules and treatments (for review of AD
functional genomic studies see (Katsel et al. 2005)). Given
the large number of microarray studies in AD brain tissues, we
selected 18 analyses of cortex and hippocampus representing
a broad scope of AD conditions studied, including compar-
isons of AD stages, different AD pathologies, AD in young vs.
old individuals, and others (Table 2). The studies used a
variety of microarray platforms including those from Incyte
Pharmaceuticals, Incyte Genomics, Clontech, Agilent, and
Affymetrix, and others (Table 2). Only studies containing
complete microarray analysis and data in format suitable for
this meta-analysis were selected. The microarray datasets
from the selected AD studies were pooled and multiply listed
genes were excluded, yielding what we define here as the
representative AD transcriptome profile. This profile
contained 5,185 up-regulated and 3,684 down-regulated
genes (Table 2).
MS is a chronic inflammatory disease of the central ner-
vous system mainly affecting white matter in which autoreac-
tive T cells attack the myelin-oligodendrocyte complex (for
review see (Noseworthy et al. 2000)). Several microarray
studies employed mouse models of MS or cells (for reviews
see (Steinman and Zamvil 2003; Mix et al. 2010)); in addition
a large number of studies evaluated gene expression in human
brain tissue from patients with MS (for review see (Lindberg
and Kappos 2006; Tajouri et al. 2007; Kinter et al. 2008; Dutta
and Trapp 2010)). These investigations involved both white
(Graumann et al. 2003; Tajouri et al. 2003; Lindberg et al.
2004) and grey matter (Dutta et al. 2006; Dutta et al. 2007;
Torkildsen et al. 2010). Some of these studies analyzed genes
altered in acute, chronic or silent lesions or normal tissue. For
the present meta-analysis we selected nine representative sets
of genes from papers listed in Table 2. Similar to AD studies, a
wide variety of microarray platforms were used. The micro-
array datasets from all nine studies were pooled and multiply
listed genes were excluded, yielding what we define here as
the MS transcriptome profile; this profile consisted of 3,922
up-regulated and 4,171 down-regulated genes (Table 2).
Two-way analysis of an overlap in gene and biological
process dysregulation between HAND and AD and HAND
and MS
The transcriptome profiles of HAND and ART-HAND were
each compared pairwise with AD and MS transcriptomes
(Table 3). A substantial number of dysregulated HAND
genes in both HAND groups were also dysregulated in
AD and MS profiles, with the actual number of common
changes depending in part upon the number of genes present
in the groups tested (Table 3). The individual lists of genes
in these groups, including Gene Symbol, Gene Title, and the
gene ontology annotations: “Entrez Gene ID” from NCBI
and “GO ID” from the Gene Ontology (GO) Consortium,
are provided under separate tabs in Online Resource 1. A total of
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665 or 35 % of altered genes identified in HAND brain and 49
or 19 % of treated HAND were also dysregulated in AD. The
proportion of common up- and down-regulated genes in HAND
and AD was about equal but marked differences were found
upon pairing ART-HAND and AD, where the proportions were
28 % and 10 %, respectively. The respective frequencies of
HAND genes dysregulated in common with MS, 254 out of
1,911 genes or 13 %, were much lower than those for HAND/
AD pairing. Interestingly, however, there were more common
down-regulated genes in ART-HAND and MS than in ART-
HAND and AD, 22 versus 13, respectively (Table 3).
To confirm the observed commonalities between the
HAND, AD, and MS at the single gene level, we performed
pairwise (HAND subgroups to AD and HAND subgroups to
MS) functional categorization of gene families by EASE
(Table 4). The five common most significantly up and
down-regulated biological pathways are listed in Table 4; a
full list of common dysregulated pathways is provided in
Online Resource 2 under category-specific tabs. Consistent
with a single-gene analysis, HAND, AD, and MS shared a
large number of dysregulated cellular processes; however, in
pairwise comparisons the identity, the relative ranking, and the
extent of process sharing as indicated by the EASE score were
different. For example, while the top four ranking dysregu-
lated processes shared by HAND, AD, and MS were immune
response, antigen presentation, and responses to bio- and
external stimuli, the statistical significance of pair-wise shar-
ing of these processes reflected in the EASE Score (ES)
ranged from 1.36×10−30 to 2.82×10−23 for the HAND-AD
pair and from 4.97×10−07 to 1.33×10−05 for the HAND-MS
pair (Table 4 and Online Resource 2). The differences between
paired HAND-AD and HAND-MS transcriptomes were even
more pronounced for common down-regulated biological
pathways. HAND and MS shared only five down-modulated
pathways in the brain, all with the low level of statistical
significance of just under ES of 0.05. Three of these pathways
involved calmodulin, which in the central nervous system is
known to regulate processes related to synaptic plasticity (Xia
and Storm 2005). In contrast, HAND and AD shared 89
down-regulated processes with ES scores under 0.05; while
the five most significant of these also included processes
related to synaptic function (i.e., synaptic transmission and
synaptic vesicle), their ES scores ranged from 3.48×10−12 to
7.59×10−10. The calmodulin binding pathway was ranked #8
in the HAND-AD pairing with significance score of 1.75×
10−8 whereas this pathway was #4 in HAND-MS with a score
of 0.044 (Table 4 and Online Resource 2).
Consistent with our analysis at the single gene level
(Table 3), ART-HAND shared fewer dysregulated biological
pathways with AD and MS and the statistical power of the
pathways in common that remained (such as immune re-
sponse) was also lower (Table 4 and Online Resource 2).
The loss of similarity was the greatest for down-modulated
biological pathways in paired ART-HAND versus AD anal-
ysis, where only four dysregulated pathways remained in
common at low significance level (compared to 89 dysregu-
lated pathways in HAND-AD pairing), and none of them
representing the highly significant common dysregulation of
neuronal functions (Table 4 and Online Resource 2). It
should be noted that ART-HAND transcriptomes showed
similarly attenuated dysregulation of gene expression when
compared to transcriptomes form untreated HAND, a find-
ing that we attributed to the beneficial effects of antiretro-
viral treatment (Borjabad et al. 2011). There is as yet no
treatment alleviating molecular and cognitive symptoms of
AD. In this context, because ART-HAND transcriptomes are
more similar to those of HIV-negative individuals than
people with untreated HAND (Borjabad et al. 2011), the
results of comparative analysis of ART-HAND and AD
profiles in the present work also can be seen as a specificity
control for the HAND-AD comparison.
The analyses presented so far indicate that untreated HAND
and AD, more than HAND and MS, share dysfunctions in
many “executive” biological pathways responsible for defec-
tive neurocognitive functions. To obtain a more detailed view
of neuropathobiological mechanisms potentially shared by
these patients, we analyzed down-regulated data using gene
ontology tool Affymetrix NetAffx™ Analysis Center (Figs. 1
and 2). Only selected genes are shown; the full lists of aberrant
genes used for this analysis are provided under dedicated tags
in Online Resource 1. We found that 61 % of down-regulated
pathways shared by HAND and AD were implicated in
broadly-defined nervous system functions such as synaptic
transmission, nervous system development, and neurocogni-
tion processes (Fig. 1). 29 % of shared dysregulated brain
processes included genes involved mostly in basic cell-
Table 3 Number and percentage of dysregulated genes in brain tissues of HAND or ART-HAND in common with AD or MS
Alzehimer’s disease (8,869 genes) Multiple sclerosis (8,093 genes)
All Up Down All Up Down
HAND (1911 genes) 665 35 % 381 34 % 284 36 % 254 13 % 170 15 % 84 11 %
ART-HAND (253 genes) 49 19 % 36 28 % 13 10 % 43 17 % 21 16 % 22 18 %
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physiological functions such as signal transduction and cell
cycle, while 10 % of common defective processes remain yet
to be defined (Fig. 1). As shown in Fig. 2, the overall distribu-
tion of pathway-categorized similarities between HAND and
MS was different from that of HAND and AD, with only 37 %
(versus 61 % in HAND-AD) of common pathways related to
nervous system function and a larger proportion (40 % versus
29 %) related to basic cellular processes. Smaller categories
(under 10 %) included calcium transport and metabolism and
cell adhesion (Fig. 2). Notably, even within similar broad
categories of biological pathways, the majority of aberrant
genes identified as common in HAND and MS were different
from those common to HAND and AD (Tables 1 and 2).
Three-way analysis of an overlap in gene and biological
process dysregulation between HAND, AD, and MS
The potential pathophysiological overlap between HAND,
AD, and MS and ART-HAND, AD, and MS is shown sche-
matically in Venn diagrams in Fig. 3. The diagrams are based
on the lists of common dysregulated genes provided in Online
Resource 1. There were 59 up-regulated and 21 down-
regulated genes in common to HAND, AD, and MS. Gene
ontology analysis of these genes (Online Resource 2) revealed
common and highly significant up-regulation of immune re-
sponse processes such as response to external stimulus, in-
flammation and innate immunity. Other up-regulated
pathways included transcription regulation, cell adhesion
and others. Only 5 down-regulated pathways scored signifi-
cantly in all three diseases including neurogenesis in position
5. This result confirms data shown in Table 4 and Figs. 1 and 2
suggesting that the mechanisms of neuronal dysfunction
shared between HAND and AD on the one hand and HAND
and MS on the other are different. We found only 7 up-
regulated and 3 down-regulated genes common to ART-
HAND, AD, and MS, in part reflecting highly reduced num-
ber of dysregulated genes found in ART-treated HAND brain
(Borjabad et al. 2011). No significant pathways were found
commonly dysregulated in these three groups.
Discussion
Comparison of gene expression profiles from brain diseases
obtained by independent studies is challenging (Glanzer et
al. 2004; Lukasiuk and Pitkänen 2004; Higgs et al. 2006;
Table 4 Five most significant up-regulated (bold) and down-regulated (italic) biological pathways in common in HAND and AD or MS and ART-
HAND and AD or MS
Alzheimer’s disease Multiple sclerosis
Gene category EASE score Gene category EASE score
HAND immune response 1.36E-30 response to external stimulus 4.97E-07
defense response 2.25E-28 immune response 2.83E-06
response to biotic stimulus 3.10E-28 response to biotic stimulus 3.63E-06
response to external stimulus 2.82E-23 defense response 1.33E-05
antigen presentation 5.30E-19 response to stress 0.0007
transmission of nerve impulse 3.48E-12 calmodulin-dependent protein kinase I activity 0.010
synaptic transmission 1.43E-11 non-kinase phorbol ester receptor activity 0.013
transport 1.15E-10 calcium/calmodulin-dependent kinase activity 0.033
cell-cell signaling 2.91E-10 calmodulin binding 0.045
synaptic vesicle 7.59E-10 phorbol ester receptor activity 0.046
ART-HAND antigen presentation 1.20E-05 immune response 0.002
antigen processing 1.20E-05 defense response 0.003
signal transducer activity 7.17E-05 response to biotic stimulus 0.005
immune response 0.0002 response to external stimulus 0.021
defense response 0.0004 antigen processing 0.022
DNA helicase activity 0.018 intracellular signaling cascade 0.005
hydrolase activity 0.025 signal transduction 0.012
cell growth and/or maintenance 0.036 catalytic activity 0.015
binding 0.038 cell communication 0.038
cellular process 0.045
Gene ontology analysis was performed using EASE software (Hosack et al. 2003). The complete list of dysregulated pathways is in Online Resource 2.
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Cooper-Knock et al. 2012). Factors such as the heterogene-
ity of brain tissue, patient-to-patient variability, disease
stage, anatomical location of samples, and technical and
study design differences all contribute to a significant vari-
ability among individual studies (Glanzer et al. 2004;
Lukasiuk and Pitkänen 2004; Higgs et al. 2006; Cooper-
Knock et al. 2012; Hawrylycz et al. 2012). However, vari-
ability does not necessarily imply irreproducibility unless
the same samples are independently analyzed and yield
different results (Sorlie et al. 2003), which was not reported
for the array datasets used in the present work. It is likely
that individual array analyses for the same disease may
represent gene profile snapshots of specific physiological
situations tested at different disease stages or different brain
anatomical sites, as we recently suggested for transcrip-
tomes of white and grey matter from brain tissues of patients
with advanced HAND (Borjabad et al. 2011). With these
caveats, we considered such non-overlapping gene expres-
sion data from the same disease as cumulative hits of gene
dysregulation for inferring tentative representative
molecular profiles of HAND, AD, and MS. Having identi-
fied specific transcripts modulated in common among these
diseases in the present study, future studies can conduct
more tailored analysis to compare similar microarray plat-
forms, similar brain regions, patients at similar ages, or
sharing other features likely to influence the analysis of
the outcome of disease. Such studies have recently been
published, for example, for AD and schizophrenia (Park et
al. 2012; Roussos et al. 2012) and are under way for HAND
in our laboratory.
One major outcome of our analysis is the demonstration
of significant similarity between HAND and AD at the brain
transcriptome level despite different etiologies of these dis-
eases. HAND is a virally-induced disease in which soluble
factors produced by HIV infected/activated macrophages,
microglia, and astrocytes induce brain inflammation, disrupt
brain homeostasis, mediate neuronal and astrocyte dysfunc-
tion, and in advanced disease lead to neuronal and astrocyte
apoptosis and dementia (Lipton and Gendelman 1995;
Lopez-Villegas et al. 1997; Ellis et al. 2007; Sailasuta et
61%
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Fig. 1 Common down-regulated genes/pathways in HAND and AD. Down-regulated genes in common in HAND and AD were classified in
biological pathways using the Affymetrix NetAffx™ Analysis Center (http://www.affymetrix.com/analysis/index.affx)
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al. 2009; Borjabad et al. 2011). Thus HAND pathogenesis
appears to be driven primarily by environmental insults to
neurons and neuronal-astrocyte networks. In contrast, AD is
primarily an auto “proteopathic” (Jucker and Walker 2011)
neurodegenerative disease initiated in neurons by misfold-
ing and aggregation of two specific proteins, amyloid-beta
and tau, which in later stages of disease form the character-
istic lesions of senile plaques and neurofibrillary tangles
(Maccioni et al. 2001; Jucker and Walker 2011; Wilcox et
al. 2011). Inflammation plays a prominent role in AD but it
appears to be secondary to amyloid-beta and tau accumula-
tion (Khandelwal et al. 2011; Zilka et al. 2012). Yet our
results suggest that the pathophysiology of HAND and AD
converges in a relatively limited number of down-regulated
genes responsible for dysfunctions linked to neuronal func-
tion and neurodegeneration including synaptic plasticity,
synaptic signal transmission, and axonal transport (Fig. 1).
Indeed, synaptodendritic injury and synaptic failure are
believed to underlie neurocognitive impairment in both
HAND and AD (Selkoe 2002; Ellis et al. 2007; Wilcox et
al. 2011). In AD, synaptic failure was correlated with accu-
mulation and post-synaptic binding of beta-amyloid
oligomers (Wilcox et al. 2011; Yu and Lu 2012) and accu-
mulation of phosphorylated tau in dendritic spines (Hoover
et al. 2010). The mechanisms of synaptic injury in HAND
are not fully understood but role of factors secreted by HIV-
infected macrophages including HIV Tat protein and
platelet-activating factor has been suggested (Lu et al.
2007; Lu et al. 2011). Regardless of the proximal stimuli
for synaptic injury, these results support the notion that
some core cellular processes mediating this impairment in
HAND and AD are similar.
In contrast to HAND and AD, while both MS and HAND
share pathologies of white matter (Navia et al. 1986b;
Noseworthy et al. 2000) they largely diverge in their respec-
tive molecular phenotypes of disease. The divergence is
consistent with the generally distinct disease phenotypes of
HAND and MS; HAND presents cognitive and behavioral
impairments with varying motor involvement (Navia et al.
1986a) while MS is mostly known as a debilitating motor
and sensory disease (for review see (Noseworthy et al.
2000)). It has been recently recognized that MS also
involves cognitive impairment (Noseworthy et al. 2000),
and indeed our analysis shows overlap between HAND
and MS in dysregulation of genes involved in synaptic
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Relatively few genes were dysregulated in common in the
three diseases analyzed here and they may represent key path-
ways involved in neurodegeneration. Most prominent among
common up-regulated pathways were immune responses, in-
cluding increased expression of CD14, CD44, MHC class I and
II genes HLADQA1 and B2M, interferon response-related
genes IRF2 and IL10RB, and complement component C4B
(Online Resources 1 and 2). Our analysis extends previous
reports on individual gene products and functions (Hoozemans
et al. 2011; Reynolds et al. 2011) consistent with the notion that
immune responses and chronic neuroinflammation are common
denominators of HAND, AD and MS. Also notable was com-
mon up-regulation of BACE2, a gene coding for an amyloid-
beta peptide that was previously linked to Alzheimer’s disease
(Holler et al. 2012). Common down-regulated genes in HAND,
AD, and MS revealed by our analysis are primarily linked to
neuronal and especially synaptic functions consistent with the
common neurocognitive impairment in the three diseases
(Navia et al. 1986a; Noseworthy et al. 2000; Maccioni et al.
2001), including CBLN2, GPM6A and CUTL2, genes linked to
synapse formation and differentiation and implicated in memory
processes (Cubelos et al. 2010); neuronal development genes
LZTS1 and NAP1L3 (Attia et al. 2011; Kropp and Wilson
2012); and the DDP6 gene that participates in regulation of
potassium-related dendritic excitability (Sun et al. 2011). Other
common down-regulated genes include calcium-related genes
CAMK2G, CACNA2D3 or CADPS2 potentially implicated in
the control synaptic plasticity and long term potentiation through
sequestration of intracellular calcium (Kawamoto et al. 2012).
Of particular interest was suppression of the GABA receptor
GABRG2, potentially impairing GABAergic neuron signal
transmission andmemory (Melzer et al. 2012) and dysregulation
of the UBE3A gene that was previously implicated in protea-
some degradation and linked to the cognitive impairment of
Angelman syndrome (Jiang et al. 2010). Also of note, the three
diseases shared down-modulation of hemoglobin B which was
recently described as a new marker of neurodegeneration in
Alzheimer’s disease and other dementias (Ferrer et al. 2011).
Clearly, additional independent analyses with larger datasets
and confirmatory RNA and protein assays are needed to sub-
stantiate these results. Nevertheless, our work indicates that
there might be a core of dysregulated processes in the brain
that are common to the three very different neurodegenerative
disorders analyzed in the present work. Convergent pathogenic
pathways were recently suggested for AD and Huntington’s
disease (Ehrnhoefer et al. 2011). Better understanding of such
putative shared processes of neuropathogenesis may direct
development of novel disease prevention strategies and
treatments.
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